NeuroSense Therapeutics (NRSN) late Friday disclosed plans by one of its larger institutional investors to sell a portion of its stake in the biotechnology company from time to time.
The company filed a preliminary prospectus Friday for Rimon Gold Assets to sell up to 11 million of its NeuroSense ordinary shares, including 4.4 million share it would receive by exercising warrants.
NeuroSense will not receive any proceeds from the secondary sale.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments